ArticleAdvanced biomedical research2025
Curcumin ZnO and MgO Nanoparticles Confer Protective Effects Against Ketamine-Induced Bipolar Disorder in Mice: Role of Brain-Derived Neurotrophic Factor.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bipolar disorder (BD), or bipolar disease, is a prevalent psychiatric condition. Current treatment options are often ineffective, with numerous side effects. Brain-derived neurotrophic factor (BDNF) may be a potential biomarker for BD. Materials and Methods: Synthesized curcumin-conjugated ZnO nanoparticles (Cur-ZnO NPs) and curcumin-conjugated MgO nanoparticles (Cur-MgO NPs) were characterized by Fourier transform infrared, field emission scanning electron microscopy, (energy dispersive X-ray analysis (EDX), and ultraviolet-visible spectrophotometry. Behavioral changes in an open field test and the level of hippocampal BDNF were evaluated in a ketamine-induced manic-depressive-like behavior mouse model. Mice were treated intraperitoneal daily for 14 days. Control mice received saline; positive control mice received 25 mg/kg ketamine. Lithium (45 mg/kg), 5 mg/kg magnesium oxide (MgO), 5 mg/kg zinc oxide (ZnO), or 40 mg/kg curcumin was administrated in separates groups simultaneously with ketamine (25 mg/kg). Mice in the treatment group were given ketamine (25 mg/kg) plus Cur-MgO NPs or Cur-ZnO NPs (10, 20, or 40 mg/kg). Results: Both nanoparticles were chemically characterized. Both nanoparticles increased central square entries, time spent in the center zone, the rearing frequency, and ambulation distance in the ketamine-treated mice in the OFT. The hippocampal BDNF levels were also increased compared to the ketamine-treated mice. Conclusion: Cur-ZnO NPs and Cur-MgO NPs may be potential candidates for treating manic-depressive-like disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.